UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 57,386 Shares of DaVita Inc. (NYSE:DVA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in DaVita Inc. (NYSE:DVA - Free Report) by 14.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 466,046 shares of the company's stock after acquiring an additional 57,386 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.57% of DaVita worth $69,697,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Invesco Ltd. raised its holdings in DaVita by 20.9% during the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock worth $237,716,000 after purchasing an additional 275,284 shares in the last quarter. Northern Trust Corp raised its holdings in shares of DaVita by 12.5% during the 4th quarter. Northern Trust Corp now owns 740,774 shares of the company's stock valued at $110,783,000 after buying an additional 82,326 shares during the period. Amundi lifted its stake in shares of DaVita by 116.4% in the fourth quarter. Amundi now owns 446,386 shares of the company's stock worth $68,726,000 after acquiring an additional 240,126 shares in the last quarter. Deutsche Bank AG lifted its holdings in DaVita by 35.2% during the 4th quarter. Deutsche Bank AG now owns 392,422 shares of the company's stock worth $58,687,000 after buying an additional 102,230 shares during the last quarter. Finally, Epoch Investment Partners Inc. bought a new position in DaVita during the 4th quarter worth $55,100,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Price Performance

DVA stock traded down $0.40 during midday trading on Friday, reaching $135.93. The company had a trading volume of 166,050 shares, compared to its average volume of 819,340. The stock has a 50 day moving average price of $144.38 and a 200-day moving average price of $153.00. The company has a market capitalization of $10.26 billion, a price-to-earnings ratio of 12.66, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 1-year low of $131.76 and a 1-year high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. The firm had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The business's revenue for the quarter was up 5.0% on a year-over-year basis. During the same period last year, the firm posted $2.26 earnings per share. Equities research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Barclays increased their price target on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. Cowen reissued a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Truist Financial dropped their price target on DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a report on Monday, May 19th. Finally, Sanford C. Bernstein set a $184.00 price objective on DaVita in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $164.50.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.